PDGF is one of the most potent serum mitogens, and the signalling mechanism by way of its receptor tyrosine-kinase has been extensively studied since its first purification in 1979. The identification of homology between the simian sarcoma virus oncogene, v-sis, and the B-chain of PDGF, as well as the frequent over-expression of both the ligands and receptors in various tumours and stroma led to the proposal of the Vol.
Although there are slight differences between the signalling molecules activated by the a-and b-receptors, major differences between the functions of the receptors derive from their expression patterns. Expression of the PDGF receptors is increased during development as well as in certain physiological and pathological conditions. The a-receptor plays important roles in the development of neural crest-derived cells and somites (Soriano, 1997; Tallquist & Soriano, 2003) , and the b-receptor, of the mural cells of blood vessels (Hellstrom et al., 1999; Lindahl et al., 1997) . Neurons and glial cells of the CNS and PNS can express PDGF and its receptors, which are considered to stimulate their proliferation, differentiation and survival (Eccleston et al., 1993; Erlandsson et al., 2001; Funa & Åhgren, 1997; Raff, 1989; Sasahara et al., 1991; Smits et al., 1993; Yeh et al., 1991) .
The PDGF b-receptor can be up-regulated in fibroblasts and blood vessels during wound healing and chronic inflammation (Reuterdahl et al., 1991; . Tumour stromal cells including vascular cells express the b-receptor in a paracrine fashion (Hermanson et al., 1988; Smits et al., 1992) . This hypothesis was supported by various experimental tumour models, in which PDGF stimulated tumour growth through the formation of stroma expressing the receptor (Forsberg et al., 1993; Skobe & Fusenig, 1998; Sundberg et al., 1997) . Recently, PDGF-specific tyrosine kinase inhibitors were shown to possess antiangiogenic effects in animal tumour models (Bergers et al., 2003; Uehara et al., 2003) . Because of the lack of specific antibodies, it had been thought that endothelial cells expressed the receptor. However, it was later found that mural cells (surrounding the endothelial cells) express the receptors. PDGF has an angiogenic activity (Li et al., 2003; Risau et al., 1992; Smits et al., 1989) , and is essential for the formation of normal blood vessels by recruiting pericytes and smooth muscle cells (Lindahl et al., 1997) . Consequently, a PDGF kinase inhibitor was shown to block growth of end-stage tumours, inducing detachment of pericytes and disruption of tumour vascularity (Bergers et al., 2003) . Recently, ligand-activated PDGF b-receptor was shown to be involved in the mechanism of increased interstitial fluid pressure in stroma in an experimental tumour model . Hence, administration of a PDGF kinase inhibitor increased tumour drug uptake, and enhanced the effects of cytotoxic drugs (Pietras et al., 2003) .
Expression of both receptors is increased in atherosclerotic blood vessels, and the a-receptor was found to be up-regulated by mechanical stress of smooth muscle cells (Fukuoka et al., 1999; Hu et al., 1998; Waltenberger et al., 1996) . In vitro, it has been shown that PDGF b-receptor expression changes markedly depending on culture conditions, such as density of cells, attachment of cells to matrix, presence of serum, as well as on the differentiation status of cells (Barrett et al., 1996; Terracio et al., 1988; Vaziri & Faller, 1996) . The receptor expression is up-regulated when cells grow in suspension and in gel, and also in cells cultured on fibronectin-coated surface. Later, fibronectin has been shown to up-regulate the transcription of PDGFRB (Tamura et al., 1998) . Furthermore, the expression was shown to be down-regulated when cells are stimulated by growth factors or oncogenes and viral transforming proteins such as Src, Myc, and SV40 large T antigen (Cook et al., 1993; Izumi et al., 2001; Oster et al., 2000; Vaziri & Faller, 1995; Wang et al., 1996; Zhang et al., 1995) . Some tumours gain enhanced mitogenic activity and other growth advantages by alterations of genes in the PDGF-system. Dermatofibrosarcoma protuberans may have a chromosomal translocation placing exon 2 of PDGF B-chain under the control of the COL1A1 promoter (Sirvent et al., 2003) . KIT and PDGFRA mutations appear to be mutually exclusive oncogenic mechanisms in gastrointestinal stromal tumours (Heinrich et al., 2003) . The hypereosinophilic syndrome may result from a novel fusion tyrosine kinase, FIP1L1-PDGFRA, that is a consequence of an interstitial deletion (Cools et al., 2003) . Expression of PDGF a-receptor is increased in malignant glioma and pulmonary artery intimal sarcoma, which can be a consequence of gene amplification of the receptor, establishing autocrine stimulation (Hui et al., 2001; Zhao et al., 2002) . Furthermore, translocation between chromosomes 5 and 12, yielding TEL-PDGFRB fusion protein was shown to be associated with some chronic myelomonocytic leukaemias (Sjöblom et al., 1999) . The majority of tumours involving the PDGF-mediated stimulation, however, use over-expression without gene alteration. PDGF a-receptor is activated in medulloblastoma, malignant glioma, and ovarian tumours (Andrae et al., 2002; Henriksen et al., 1993; Hermanson et al., 1992; MacDonald et al., 2001) . Consistent with these observations, recent therapeutic trials using PDGF-specific tyrosine kinase inhibitors have shown promising results (Östman & Heldin, 2001 ).
PDGF RECEPTOR GENES AND THEIR TRANSCRIPTION
The genomic structure and organization of PDGF receptor genes are similar. The PDGFRA and PDGFRB genes span approximately 69 kb and 43 kb, respectively, and contain 23 exons. The 5¢-untranslated region of the mRNA is encoded by exon 1, and a large intron of 23 kb separates exon 2 encoding the translation initiator codon AUG and the signal sequence. These two PDGF receptors are also very similar as concerns the locations of exon/intron boundaries in the extracellular immunoglobulin-like domains, the transmembrane domain, the two cytoplasmic tyrosine kinase domains, and the kinase insertion domain. Their organisation also resembles that of the genes encoding stem cell factor (SCF) receptor, KIT, granulocyte-macrophage colony stimulating factor receptor (GM-CSF1R) Vol. 50 Regulatory mechanism of PDGF receptor expressionand macrophage colony stimulating factor receptor (M-CSF1R). Human KIT and PDGFRA are located within Ch 4q11-q13, and human PDGFRB and CSF1R exist in tandem in Ch 5q31-32 and 5q33-35, respectively (Kawagishi et al., 1995) ; see <www.ncbi.nlm.nih.gov/ LocusLink>. Once the promoters of the receptors had been isolated, in vitro studies on the transcriptional regulation of the receptor expression became possible (Afink et al., 1995; Ballagi et al., 1995; Kawagishi et al., 1995; Kitami et al., 1998; Shinbrot et al., 1997; Wang & Stiles, 1994) . The transcription start site is approximately 400 bp upstream of the AUG translation initiation codon. The 5¢-flanking region of the gene lacks a typical TATA box but contains a typical CCAAT box and GATA motifs. This region also contains potential sites for AP-1 and Sp1.
In this review, we focus on the PDGFRB promoter that we study in our laboratory. The PDGFRB promoter contains a CCAAT motif that binds the NF-Y transcription factor (Ballagi et al., 1995; Ishisaki et al., 1997) . Sp1 binds the upstream GC-rich domain close to the NF-Y binding site and activates the transcription . NF-Y specifically recognises the CCAAT motif found in various promoters and enhancer regions of many eukaryotic genes (Mantovani, 1998) . NF-Y consists of subunits A, B, and C, and the B and C subunits dimerise through the conserved histone-fold motif (HFM) to interact with the subunit A (Kim et al., 1996) .
The transcription of PDGFRB becomes down-regulated after growth factor stimulation (Oster et al., 2000; Vaziri & Faller, 1995) . Growth factor stimulation of cells induces c-Myc expression, which upon binding to the partner protein Max, enters the nucleus. The Myc-Max complex binds to the consensus E-box sequence and stimulates the transcription of several genes necessary for DNA synthesis. Recently, c-Myc was shown to repress the PDGFRB transcription through binding and inactivation of NF-Y. The N-terminal transactivation domain of Myc is indispensable for the binding and repression of the transcription. Since PDGF activates Src-kinase, which in turn activates Myc (Barone & Courtneidge, 1995) , the Myc-induced receptor repression may be considered a negative feedback following PDGF activation. This mechanism might be involved in the previously reported down-regulation of the PDGF receptor following oncogene expression and changes in the growth conditions of cells.
In addition to c-Myc, the suppressor p73a directly represses the transcription of PDGFRB (Hackzell et al., 2002) . Although p73 can be induced by Myc (Zaika et al., 2001) , and they also bind each other , p73a represses the receptor transcription in Myc-null cells by an independent mechanism. p73 belongs to the p53 tumour suppressor protein family and exists in several C-terminal splicing isoforms (Irwin & Kaelin, 2001 ). Some of the isoforms exist also as N-terminal deleted variants (DNp73) that lack the transactivation domain, acting as dominant-negative molecules through competing with the full-length isoforms for DNA-binding and oligomerisation. The mechanism of the p73a mediated repression was shown to be similar to that used by Myc. The physical interaction of the C-terminal SAM domain of p73a with NF-YB and -YC prevents the NF-Y-mediated transactivation of the PDGFRB promoter (Hackzell et al., 2002) . In contrast, DNp73a activates the PDGFRB promoter, which is likely to be one of the reasons for the constitutive elevated expression of PDGF b-receptor in certain neuroblastoma cell lines (Hackzell et al., unpublished observation) . However, the exact mechanism for how p73a represses NF-Y activity has not been completely elucidated. Our preliminary results suggest that p73a competes for NF-Y binding with co-activators such as p300 and P/CAF, both possessing histone acetyltransferase (HAT) activity (Uramoto et al., unpublished observation) . A similar mechanism might be involved in the Myc-induced repression. SV40 large T antigen represses the receptor expression also at the transcriptional level, partly through the induction of Myc but also through binding to p53. In fact, p53 seems to be an important activator of the transcription of PDGFRB (Uramoto et al., unpublished observation) . This tight transcriptional control by several proteins that are essential for cell cycle control may underscore the importance of regulated growth factor stimulation for normal cell growth. Transcriptional regulation seems to be one of the most long-lasting mechanisms to control the activity of the PDGF-receptors.
OTHER POTENTIAL NEGATIVE REGULATORY MECHANISMS FOR THE PDGF b-RECEPTOR
Dimerisation of the receptors leads to autophosphorylation and activation of the receptor kinase. The phosphorylated tyrosine residues create binding sites for the SH2 domains of several intracellular signalling molecules. They are typically phosphatidylinositol 3-kinase (PI3K), the adaptor molecule Grb2 that forms a complex with Sos1, the nucleotide exchange molecule acting on Ras, phospholipase Cg (PLCg), the tyrosine kinase Src, the tyrosine phosphatase SHP2, and RasGAP, a GTPase-activating protein (Heldin et al., 1998) . These molecules directly or indirectly activate downstream kinases, leading to the activation of transcription factors to initiate target gene transcription. Alternatively, these kinases can directly or indirectly activate or inactivate target molecules involved in apoptosis, cell motility or other cellular functions.
The expression of PDGF receptors is tightly regulated not only at the transcriptional level but also at the protein level. When PDGF binds to the receptor, the dimerised receptors become internalised. These ligand-bound PDGF b-receptors remain activated and tyrosine phosphorylated after internalisation (Sorkin et al., 1993) . The ligand-bound receptors are accumulated in both clathrin-coated endosomes and membrane invaginations, caveolae (Kapeller et al., 1993; Yamamoto et al., 1999) . The internalisation results in a transient decrease of the receptors on cell membranes. PDGF receptors directly interact with caveolin subtypes, which inhibit the activation of PDGF receptor kinase (Yamamoto et al., 1999) . However, it has also been shown that the PDGF-receptor internalisation could be involved in MAPK activation rather than constituting a down-regulation of the signal (Chiarugi et al., 2002; Rakhit et al., 2000) .
Cbl is one of the SH2-domain-containing proteins that bind phosphotyrosine of the PDGF receptors. Upon phosphorylation, Cbl, being a proteasomal E3-like ubiquitin ligase for the receptor, leads to a rapid degradation of PDGF receptors via a proteasomal pathway (Miyake et al., 1999) . However, the overall PDGF-receptor protein degradation upon PDGF stimulation, as estimated by Chiarugi et al. (2002) , was around 30-40 percent of the total receptors, and the receptors were shown to be functionally active for further stimulation.
Several phosphotyrosine phosphatases (PTPs) bind the phosphotyrosine residues of the receptors through a transient enzymesubstrate interaction as well as through their SH2 domains, rendering dephosphorylation of the PDGF receptors. This accounts for one of the major controlling mechanisms for the activity of the receptors. Several PTPs -PTP-PEST, SHP-2, an active fragment of SHP-2, PTP-1B, and T-cell PTP -have been shown to bind PDGF b-receptor by an in-gel assay (Markova et al., 2003) , with SHP-2 being the most efficiently binding PTP. By binding and dephosphorylation of the PDGF receptor, and possibly of its substrates, SHP-2 can act negatively on the signalling. However, SHP-2 is also known to play an important role in mitogenic signalling (Roche et al., 1996) . It is possible that the SHP2-bound PDGF receptor can recruit the adaptor protein Grb2, which, Vol. 50 Regulatory mechanism of PDGF receptor expressionin turn, brings the Ras exchange factor (Sos) to its target, leading to activation of MAP kinases. A similar mechanism was proposed for signal transduction via E-selectin (Hu et al., 2001) . Cells with the SHP-2 binding mutant PDGF b-receptor (Y763F/Y1009F) were not only decreased in MAP kinase activation, but also significantly decreased in PDGF-BB-induced chemotaxis, without changing the mitogenic response to PDGF (Rönnstrand et al., 1999) . Thus, SHP-2 plays a dual role in PDGF signalling, and is implicated in both positive and negative signalling. Low molecular weight phosphotyrosine phosphatase (LMW-PTP) has also been shown to be able to bind and dephosphorylate Y857 of activated PDGF receptor, inhibiting cell proliferation. Binding of LMW-PTP down-regulates most of the PDGF activated signalling molecules such as PI3-kinase, SHP-2, and PLC-g1, but not MAP kinases (Chiarugi et al., 1998) . The authors also reported that LMW-PTP exists constitutively in the cytosol, associated with the cytoskeleton. Upon PDGF stimulation, c-Src is able to bind and phosphorylate LMW-PTP only in the cytoskeleton-associated fraction. As a consequence of phosphorylation, the catalytic activity of LMW-PTP increases (Chiarugi et al., 2002) .
EFFECTS OF VARIOUS STIMULI ON PDGF RECEPTOR EXPRESSION
In addition to the self-regulatory mechanisms elicited by the activation of the receptor, the interaction with other signalling systems is extensive. General conclusions are difficult to draw since conditions and cell types differ among published studies. Some reported findings are described below.
Transforming growth factor-b1 (TGF-b1) has been shown to decrease PDGF a-receptor expression in various cell types such as human primary bronchial SMC (Bonner et al., 1996) , lung fibroblasts (Lindroos et al., 1997) , a human foreskin fibroblast cell line (Paulsson et al., 1993) , and normal mesothelial cells (Langerak et al., 1996) . However, the results on the effects of TGF-b on PDGF b-receptor vary in different cell types: in most cell types, no change was observed, but in certain cell types, i.e. human fat-storing cells, up-regulation was reported (Pinzani et al., 1995) . The reason for this variability might depend on the growth conditions of cells, as was mentioned before. bFGF increased PDGF a-receptor expression without altering PDGF b-receptor expression in human primary bronchial SMC (Bonner et al., 1996) . IL1b did not affect the expression of PDGF receptors on the SMC, but enhanced PDGF a-receptor expression on lung fibroblasts (Lindroos et al., 1997) .
In human osteoblastic cells, TNF-a decreased PDGF a-receptor both at the mRNA and at the protein level (Gravestein & Borst, 1998) , whereas in human fibroblasts, TNF-a decreased the expression of PDGF b-receptor without affecting PDGF a-receptor (Battegay et al., 1990; Tingström et al., 1992) . However, TNF-a did not change the expression of PDGF b-receptor in mouse L1 fibroblasts but suppressed the ligand-stimulated PDGF b-receptor-tyrosine kinase phosphorylation (Molander et al., 2000) .
CONCLUSION
More than two decades ago PDGF, A and B, as well as their receptors were isolated. However, new family members continue to be discovered, adding further complexities to the system. Consistent with the essential roles of PDGF in growth and survival of cells, there is a tight control of the expression and activity of PDGF receptors through positive as well as negative feedback systems. Deregulation of the control systems has been implicated in serious pathological conditions such as chronic inflammation and tumours. Understanding of the mechanisms behind the growth factor system may lead to new therapeutic possibilities.
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